Login
Super Investors Tema Oncology ETF

Tema Oncology ETF

Tema ETF Trust · net assets $211M · 59 holdings as of August 31, 2026. Monthly N-PORT disclosure: the full book, not just equities.

Asset mix

EC: 99.6% · STIV: 0.4%

Financial position

Total assets
$213M
Total liabilities
$2.04M
Net assets
$211M
Assets attributable to miscellaneous securities
$0
Assets invested in controlled foreign corporations
$0
Borrowings payable within one year
$0
Payable to controlled companies within one year
$0
Payable to other affiliates within one year
$0
Other liabilities payable within one year
$0
Borrowings payable after one year
$0
Payable to controlled companies after one year
$0
Payable to other affiliates after one year
$0
Other liabilities payable after one year
$0
Payables for delayed-delivery investments
$0
Payables for standby commitments
$0
Liquidation preference of outstanding preferred stock
$0

Monthly flows and gains

Month 1 Month 2 Month 3
Sales $7.38M $9.61M $4.71M
Reinvestment $0 $0 $0
Redemptions $8.05M $3.78M $0
Net realized gain (non-derivative) $4.89M $3.13M $1.08M
Net unrealized appreciation (non-derivative) $9.72M -$5.68M $12M

The three months of the reporting period, as filed; month 3 ends August 31, 2026.

Filing details

Registrant
Tema ETF Trust
Registrant CIK
1944285
Registrant LEI
549300JKGDXNE2CLUY37
Series
Tema Oncology ETF
Series ID
S000078299
Series LEI
549300N3IU4YD19QLF24
SEC file number
811-23823
Address
575 5th Avenue, 14th Floor, New York, US-NY, 10017, US
Phone
3024994928 EXT 801
Form
NPORT-P
Filed
October 30, 2026
Report period ends
February 28, 2027
Report month ends
August 31, 2026
Accession number
000119312526441391
Holding Value % of net assets
Revolution Medicines Inc EC $12.7M 6.02%
Eli Lilly & Co EC $10.9M 5.15%
Cogent Biosciences Inc EC $9.92M 4.70%
Roche Holding Ag EC $8.81M 4.17%
Novartis Ag EC $8M 3.79%
Bristol-myers Squibb Co EC $7.54M 3.57%
Merck & Co Inc EC $7.52M 3.56%
Abbvie Inc EC $7.01M 3.32%
Halozyme Therapeutics Inc EC $6.73M 3.19%
Beone Medicines Ltd EC $6.71M 3.18%
Johnson & Johnson EC $6.53M 3.09%
Immunome Inc EC $6.33M 3.00%
Genmab A/s EC $6.08M 2.88%
Cg Oncology Inc EC $5.83M 2.76%
Ideaya Biosciences Inc EC $5.71M 2.70%
Exelixis Inc EC $5.54M 2.63%
Bridgebio Pharma Inc EC $4.92M 2.33%
Amgen Inc EC $4.34M 2.06%
Enliven Therapeutics Inc EC $4.31M 2.04%
Astrazeneca PLC EC $4.21M 2.00%
Legend Biotech Corp EC $4.11M 1.95%
Zai Lab Ltd EC $4.11M 1.95%
Celcuity Inc EC $3.82M 1.81%
Erasca Inc EC $3.72M 1.76%
Relay Therapeutics Inc EC $3.4M 1.61%
Iovance Biotherapeutics Inc EC $3.3M 1.56%
Zymeworks Inc EC $3.25M 1.54%
Nuvation Bio Inc EC $2.77M 1.31%
Urogen Pharma Ltd EC $2.64M 1.25%
Arcus Biosciences Inc EC $2.55M 1.21%
Kura Oncology Inc EC $2.17M 1.03%
Gilead Sciences Inc EC $2.14M 1.02%
Tyra Biosciences Inc EC $2.14M 1.01%
Summit Therapeutics Inc EC $2.04M 0.97%
Corvus Pharmaceuticals Inc EC $2M 0.95%
Natera Inc EC $1.96M 0.93%
Tango Therapeutics Inc EC $1.87M 0.89%
Anaptysbio Inc EC $1.87M 0.88%
Immatics Nv EC $1.71M 0.81%
Replimune Group Inc EC $1.66M 0.79%
Immunocore Holdings PLC EC $1.63M 0.77%
Cullinan Therapeutics Inc EC $1.45M 0.69%
Guardant Health Inc EC $1.4M 0.66%
Oric Pharmaceuticals Inc EC $1.29M 0.61%
Candel Therapeutics Inc EC $1.13M 0.53%
Syndax Pharmaceuticals Inc EC $1.06M 0.50%
Janux Therapeutics Inc EC $983K 0.47%
Inhibrx Biosciences Inc EC $898K 0.43%
Olema Pharmaceuticals Inc EC $871K 0.41%
Bicara Therapeutics Inc EC $867K 0.41%
Bridgebio Oncology Therapeutic EC $860K 0.41%
Cytomx Therapeutics Inc EC $811K 0.38%
Arvinas Inc EC $810K 0.38%
First American Treasury Obliga STIV $808K 0.38%
First Tracks Biotherapeutics I EC $804K 0.38%
Moderna Inc EC $736K 0.35%
Adlai Nortye Group Ltd EC $659K 0.31%
Arrivent Biopharma Inc EC $653K 0.31%
Autolus Therapeutics PLC EC $630K 0.30%

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support